Feminizing Hormone Therapy Prescription Patterns and Cardiovascular Risk Factors in Aging Transgender Individuals in Australia

MI Balcerek; BJ Nolan; A Brownhill; P Wong; P Locke; JD Zajac; AS Cheung

Journal article

Feminizing Hormone Therapy Prescription Patterns and Cardiovascular Risk Factors in Aging Transgender Individuals in Australia

MI Balcerek, BJ Nolan, A Brownhill, P Wong, P Locke, JD Zajac, AS Cheung

Frontiers in Endocrinology | FRONTIERS MEDIA SA | Published : 2021

DOI: 10.3389/fendo.2021.667403

Download PDF

Abstract

Context: The safety and efficacy of feminizing hormone therapy in aging transgender (trans) individuals is unclear. Current recommendations suggest transdermal estradiol beyond the age of 45 years, especially if cardiometabolic risk factors are present. Objective: To evaluate feminizing hormone therapy regimens and cardiovascular risk factors in aging trans individuals. Design: Retrospective cross-sectional analysis. Setting: Primary care and endocrine specialist clinic in Melbourne, Australia. Participants: Trans individuals on feminizing therapy for ≥6 months. Main Outcomes Measures: Feminizing hormone regimens and serum estradiol concentrations by age group: (a) ≥45 years, (b) <45 years, ..

View full abstract

University of Melbourne Researchers

Jeffrey Zajac Author

Ada Cheung Author

Brendan Nolan Author

Related Projects (2)

EFFECTS OF TESTOSTERONE AND OESTROGEN ON BODY COMPOSITION

Masculinising and feminising hormones such as testosterone and oestrogen respectively are important hormones controlling the amount of muscl..

Safety and quality of life of peri-operative transdermal estradiol continuation during gender affirmation surgery in transgender women: a randomised placebo-controlled trial

Despite no clear evidence, transgender women are told to stop their feminising estrogen treatment several weeks before gender surgery, but t..

Grants

Awarded by Sylvia and Charles Viertel Charitable Foundation

Funding Acknowledgements

BN is a recipient of a National Health and Medical Research Council Postgraduate Scholarship (#2003939). AC is supported byan Australian Government National Health and Medical Research Council Early Career Fellowship (#1143333) and receives researchsupport from the Viertel Charitable Foundation Clinical Investigator Award, Endocrine Society of Australia, Austin Medical Research Foundation, and the Royal Australasian College of Physicians Foundation.